Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) went up by 14.24% from its latest closing price compared to the recent 1-year high of $18.42. The company’s stock price has collected 26.11% of gains in the last five trading sessions. Press Release reported on 08/11/21 that PM360 Announces 2021 Trailblazer Award Finalists
Is It Worth Investing in Verrica Pharmaceuticals Inc. (NASDAQ :VRCA) Right Now?
Opinions of the stock are interesting as 6 analysts out of 6 who provided ratings for Verrica Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $21.50, which is $7.54 above the current price. VRCA currently public float of 9.90M and currently shorts hold a 20.04% ratio of that float. Today, the average trading volume of VRCA was 73.45K shares.
VRCA’s Market Performance
VRCA stocks went up by 26.11% for the week, with a monthly jump of 25.77% and a quarterly performance of 26.91%, while its annual performance rate touched 55.46%. The volatility ratio for the week stands at 10.14% while the volatility levels for the past 30 days are set at 8.03% for Verrica Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is 29.96% for VRCA stocks with a simple moving average of 15.77% for the last 200 days.
Analysts’ Opinion of VRCA
Many brokerage firms have already submitted their reports for VRCA stocks, with RBC Capital Mkts repeating the rating for VRCA by listing it as a “Outperform.” The predicted price for VRCA in the upcoming period, according to RBC Capital Mkts is $19 based on the research report published on May 14th of the current year 2021.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see VRCA reach a price target of $21, previously predicting the price at $18. The rating they have provided for VRCA stocks is “Buy” according to the report published on December 24th, 2020.
VRCA Trading at 28.05% from the 50-Day Moving Average
After a stumble in the market that brought VRCA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.21% of loss for the given period.
Volatility was left at 8.03%, however, over the last 30 days, the volatility rate increased by 10.14%, as shares surge +31.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +19.73% upper at present.
During the last 5 trading sessions, VRCA rose by +26.11%, which changed the moving average for the period of 200-days by +60.83% in comparison to the 20-day moving average, which settled at $10.91. In addition, Verrica Pharmaceuticals Inc. saw 21.29% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at VRCA starting from White Ted, who purchase 4,000 shares at the price of $9.95 back on Jun 04. After this action, White Ted now owns 21,966 shares of Verrica Pharmaceuticals Inc., valued at $39,800 using the latest closing price.
Hayes Christopher G., the Chief Legal Officer of Verrica Pharmaceuticals Inc., purchase 2,500 shares at $9.79 during a trade that took place back on Jun 04, which means that Hayes Christopher G. is holding 2,500 shares at $24,475 based on the most recent closing price.
Stock Fundamentals for VRCA
The total capital return value is set at -59.17, while invested capital returns managed to touch -85.25. Equity return is now at value -77.70, with -40.10 for asset returns.
Based on Verrica Pharmaceuticals Inc. (VRCA), the company’s capital structure generated 112.79 points at debt to equity in total, while total debt to capital is 53.01. Total debt to assets is 50.17, with long-term debt to equity ratio resting at 5.13. Finally, the long-term debt to capital ratio is 2.41.
The liquidity ratio also appears to be rather interesting for investors as it stands at 1.71.